Genzyme
Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review
April 16, 2019Manufacturing and Production, Sales and Marketing EMA, Genzyme, Lemtrada, multiple sclerosis, pharma
The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues …
Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
April 8, 2019Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
PureTech’s Vedanta Biosciences appoints former Genzyme VP chief scientific officer
March 16, 2016Medical Communications, Research and Development Bruce Roberts, Genzyme, Vedanta Biosciences
Vedanta Biosciences, a company developing therapies designed to modulate the human microbiome, has appointed former Genzyme group vice president, Bruce …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Companies face mixed fortunes in ultra-orphan approvals
November 26, 2015Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs
UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial
October 7, 2015Research and Development Genzyme, MS, Sanofi
Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …
Genzyme opts into Alnylam’s Thrombosis program
October 2, 2015Medical Communications, Research and Development Alnylam, Genzyme, Sanofi, haemophilia
Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in …
Sanofi sales boosted by rare disease and multiple sclerosis drugs
July 30, 2015Manufacturing and Production, Sales and Marketing Genzyme, Oliver Brandicourt, Sanofi, brandicourt, financial results
Sales at pharma giant Sanofi increased by 5% in the second quarter of 2016 to nearly €10 billion, its latest …
Sanofi makes gene therapy move
February 13, 2015Research and Development, Sales and Marketing Genzyme, Sanofi, Voyager Therapeutics, gene therapy, merger
Sanofi has signalled its intent to develop gene therapy treatments for nerve diseases through a $745 million deal with US …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
FDA green lights Lemtrada for MS
November 17, 2014Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera
The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …
FDA approves Sanofi’s new rare disease drug
August 20, 2014Research and Development, Sales and Marketing Elelyso, Gaucher disease, Genzyme, Sanofi, eliglustat
Sanofi’s biologics unit Genzyme has been granted approval for a new drug to treat the rare genetic disorder Gaucher’s disease. …
Priority review for Gaucher drug
December 12, 2013Sales and Marketing EMA, FDA, Gaucher, Genzyme, Sanofi
The FDA is to conduct a speedy investigation into Sanofi’s twice-daily oral candidate for Gaucher disease, which means that Cerdelga …
